［1］中华医学会血液学分会白血病淋巴瘤学组.成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2017年版).中华血液学杂志，2017，38 (3): 177-182.

［2］ ARBER DA, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia. Blood, 2016 May19, 127 (20): 2391-2405.

［3］NCCN clinical practice guidelines in oncology acute myeloid leukemia. Version 3. 2019. http: //www. nccn. org.

［4］ DÖHNER H, ESTEY E, GRIMWADE D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016 Nov 28. pii: blood-2016-08-733196. [Epub ahead of print].

［5］ YANG X, WANG J. Precision therapy for acute myeloid leukemia. J Hematol Oncol, 2018 Jan 5, 11 (1): 3.

［6］ SORROR ML, STORER BE, FATHI AT, et al. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol, 2017 Dec 1, 3 (12): 1675-1682.

［7］ KLEPIN HD, GEIGER AM, TOOZE JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood, 2013 May 23, 121 (21): 4287-4294.

［8］ PAUTAS C, MERABET F, THOMAS X, et al. Randomized study of intensi fi ed anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol, 2010 Feb 10, 28 (5): 808-814.

［9］ LÖWENBERG B, OSSENKOPPELE GJ, VAN PUTTEN W, et al. Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med, 2009 Sep 24, 361 (13): 1235-1248.

［10］ WELCH JS, PETTI AA, MILLER CA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med, 2016 Nov 24, 375 (21): 2023-2036.

［11］ DINARDO CD, PRATZ K, PULLARKAT V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood, 2019 Jan 3, 133 (1): 7-17.

［12］ WEI AH, STRICKLAND SA JR, HOU JZ, et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ⅰb/ⅡStudy. J Clin Oncol, 2019 May 20, 37 (15): 1277-1284.